Simon Taylor: We need to deal with technological debt at clinical sites

Send us Fan MailThis week we speak to Simon Taylor, Head of European Solutions Consulting at Florence Healthcare. We focus on site oriented technology transformation. We speak about the current challenges that clinical sites face, such as the high degree of churn within the healthcare industry, the increasing complexity of protocols and the prevalence of paper as the primary recording mechanism. We speak about how to help sites quit their paper dependencies, and how the regulatory landscape stands in the way of adapting more digital ways of working.  Sites have been given technologies to use by the sponsors that have not worked for them in the past - and have created an expectation that technology will not help make the process easier. We speak about the discrepancies between CROs, sponsors and sites. And how there is room for improvement to ensure that everyone wins from collaboration. Decentralized clinical trials are not well equipped to adopt additional technologies unless they can successfully move all of their processes into a more digital operating model on a more fundamental level.  The regulatory agencies have been encouraging diversity in clinical trial recruitment. Representation in research is currently skewed, so additional focus is needed. But it translates into a new kind of work for clinical sites - of physically going to new areas to recruit patients. Guest:Simon Taylorhttps://www.linkedin.com/in/simon-taylor-56143638/Florence Healthcarehttps://www.florencehc.com/ Visit Labtolives.com Do you want to try the quiz from this episode? Find the link on our LinkedIn profile: https://www.linkedin.com/company/labtolives/ Would you like to join the show as a guest or collaborator? Find out how on our website: https://www.labtolives.com/ Support the show________Reach out to Ivanna RosendalJoin the conversation on our LinkedIn pageVisit www.labtolives.com HostsAlexander Booth aka the MedTech GuyDimitri Borisevich aka the start-up GuyIvanna Rosendal aka the R&D pharma Gal